<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-2-12-03-2026-shutterstock_2344796289-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-2-12-03-2026-shutterstock_2344796289-430x241.jpg"/></p>
<p>該疫苗是一種單劑量預填充產品，用於對 12 歲及以上個體進行基孔肯雅病毒的免疫接種。圖片來源：Kitsawet Saethao / Shutterstock.com。</p>
<p>巴伐利亞諾迪克與印度血清研究所（SII）簽署了一項製造協議，通過該合同擴大其戰略合作伙伴關係，涉及其基孔肯雅疫苗（CHIKV VLP）。</p>
<p>該合同涵蓋了從巴伐利亞諾迪克到 SII 的疫苗製造工藝的全面技術轉讓，旨在提高生產能力併為地方性低收入和中等收入國家的未來供應提供保障。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - 埃博拉 [安卡拉巴伐利亞諾迪克菌株] (多價...</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - (惡性瘧原蟲 + 乙型肝炎) 疫苗</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>這一新安排建立在兩家公司現有的 mpox 疫苗許可和製造合作伙伴關係的基礎上。</p>
<p>它取代了與生物 E 的早期協議。雙方還將探索作為這一擴展合作的一部分的潛在共同開發機會。</p>
<p>巴伐利亞諾迪克的總裁兼首席執行官保羅·查普林表示：“我們很高興能夠加強與印度血清研究所的戰略合作伙伴關係。</p>
<p>“通過利用兩家組織的優勢，我們可以擴大基孔肯雅疫苗的生產，以增加全球供應並改善全球人羣的獲取。”</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>來自 GlobalData</p>
<p>瞭解更多關於戰略情報</p>
<p>CHIKV VLP 疫苗是一種預填充的單劑量、加佐劑的類病毒顆粒重組蛋白產品，旨在對 12 歲及以上人羣進行針對基孔肯雅病毒引起的疾病的主動免疫接種。</p>
<p>它旨在觸發強烈的血清反應，保護性免疫將在接種後的一週內開始發展。</p>
<p>由於不含病毒遺傳物質，該疫苗是非傳染性的，無法引起疾病，適合廣泛的人羣。</p>
<p>以 Vimkunya 為名，CHIKV VLP 於 2025 年獲得英國藥品和保健產品監管局（MHRA）、歐洲委員會和美國食品藥品監督管理局（FDA）的批准。</p>
<p>目前在加拿大和瑞士進行監管審查。</p>
<p>2025 年 9 月，巴伐利亞諾迪克在英國推出了其基孔肯雅疫苗 Vimkunya。</p>
<p>此次推出是在全國報告的與旅行相關的疾病病例顯著增加之後進行的。英國健康安全局（UKHSA）表示，與 2024 年同期相比，2025 年 8 月的病例增加了 170%。</p>

醫藥突破 ETF - ALPS

IBBQ

紐交所高增長板生物技術指數 ETF - First Trust

納斯達克生物科技指數 ETF - iShares Nasdaq

2 倍做多納斯達克生物技術 ETF - ProShares

標普生物技術 ETF - SPDR

BVNRY

動態生物技術與基因組 ETF - Invesco

生物科技 ETF - VanEck Vectors

<p>巴伐利亞諾迪克公司與印度血清研究所（SII）簽署了一項協議，進行基孔肯雅病毒疫苗生產技術轉讓，以增強低收入和中等收入國家的生產能力。該合作建立在他們現有的 mpox 疫苗合作基礎上，並取代了與生物 E 公司的先前協議。CHIKV VLP 疫苗以 Vimkunya 為品牌，在英國、歐盟和美國獲得了監管機構的批准，目前正在加拿大和瑞士進行審查。該疫苗旨在改善全球獲取，並因英國疾病病例的增加而顯示出顯著的需求增長</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-2-12-03-2026-shutterstock_2344796289-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-2-12-03-2026-shutterstock_2344796289-430x241.jpg"/></p>
<p>The vaccine is a single-dose, prefilled product for immunisation against the chikungunya virus in individuals aged 12 and above. Credit: Kitsawet Saethao / Shutterstock.com.</p>
<div class="lb-trans"><p>該疫苗是一種單劑量預填充產品，用於對 12 歲及以上個體進行基孔肯雅病毒的免疫接種。圖片來源：Kitsawet Saethao / Shutterstock.com。</p>
</div><p>Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract for its chikungunya vaccine (CHIKV VLP).</p>
<div class="lb-trans"><p>巴伐利亞諾迪克與印度血清研究所（SII）簽署了一項製造協議，通過該合同擴大其戰略合作伙伴關係，涉及其基孔肯雅疫苗（CHIKV VLP）。</p>
</div><p>The contract covers a full technology transfer for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to increase production capacity and future supply for endemic low- and middle-income countries.</p>
<div class="lb-trans"><p>該合同涵蓋了從巴伐利亞諾迪克到 SII 的疫苗製造工藝的全面技術轉讓，旨在提高生產能力併為地方性低收入和中等收入國家的未來供應提供保障。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - Ebola [Ankara Bavarian Nordic Strain] (Multiva...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - 埃博拉 [安卡拉巴伐利亞諾迪克菌株] (多價...</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - (plasmodium falciparum + hepatitis B) vaccine</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - (惡性瘧原蟲 + 乙型肝炎) 疫苗</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>The new arrangement builds upon the existing licence and manufacturing partnership between the two companies for the mpox vaccine.</p>
<div class="lb-trans"><p>這一新安排建立在兩家公司現有的 mpox 疫苗許可和製造合作伙伴關係的基礎上。</p>
</div><p>It replaces an earlier deal with Biological E. Both parties will also explore potential co-development opportunities as part of this extended collaboration.</p>
<div class="lb-trans"><p>它取代了與生物 E 的早期協議。雙方還將探索作為這一擴展合作的一部分的潛在共同開發機會。</p>
</div><p>Bavarian Nordic’s president and CEO Paul Chaplin said: “We are pleased to strengthen our strategic partnership with Serum Institute of India.</p>
<div class="lb-trans"><p>巴伐利亞諾迪克的總裁兼首席執行官保羅·查普林表示：“我們很高興能夠加強與印度血清研究所的戰略合作伙伴關係。</p>
</div><p>“By leveraging the strengths of both organisations, we can scale manufacturing of our chikungunya vaccine to expand global supply and improve access for populations around the globe.”</p>
<div class="lb-trans"><p>“通過利用兩家組織的優勢，我們可以擴大基孔肯雅疫苗的生產，以增加全球供應並改善全球人羣的獲取。”</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>來自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>The CHIKV VLP vaccine is a prefilled, single-dose, adjuvanted virus-like particle recombinant protein product intended for active immunisation against disease caused by the chikungunya virus in people aged 12 years and above.</p>
<div class="lb-trans"><p>CHIKV VLP 疫苗是一種預填充的單劑量、加佐劑的類病毒顆粒重組蛋白產品，旨在對 12 歲及以上人羣進行針對基孔肯雅病毒引起的疾病的主動免疫接種。</p>
</div><p>It is designed to trigger a strong seroresponse, with protective immunity beginning to develop as soon as one week following vaccination.</p>
<div class="lb-trans"><p>它旨在觸發強烈的血清反應，保護性免疫將在接種後的一週內開始發展。</p>
</div><p>As it does not contain viral genetic material, the vaccine is non-infectious and cannot cause disease, making it suitable for a broad population demographic.</p>
<div class="lb-trans"><p>由於不含病毒遺傳物質，該疫苗是非傳染性的，無法引起疾病，適合廣泛的人羣。</p>
</div><p>Marketed as Vimkunya, CHIKV VLP has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the European Commission, and the US Food and Drug Administration (FDA) in 2025.</p>
<div class="lb-trans"><p>以 Vimkunya 為名，CHIKV VLP 於 2025 年獲得英國藥品和保健產品監管局（MHRA）、歐洲委員會和美國食品藥品監督管理局（FDA）的批准。</p>
</div><p>Regulatory review is underway in Canada and Switzerland.</p>
<div class="lb-trans"><p>目前在加拿大和瑞士進行監管審查。</p>
</div><p>In September 2025, Bavarian Nordic launched its chikungunya vaccine, Vimkunya, in the UK.</p>
<div class="lb-trans"><p>2025 年 9 月，巴伐利亞諾迪克在英國推出了其基孔肯雅疫苗 Vimkunya。</p>
</div><p>The launch followed a significant increase in travel-related disease cases reported nationwide. The UK Health Security Agency (UKHSA) stated that incidences rose by 170% in August 2025 compared with the same period in 2024.</p>
<div class="lb-trans"><p>此次推出是在全國報告的與旅行相關的疾病病例顯著增加之後進行的。英國健康安全局（UKHSA）表示，與 2024 年同期相比，2025 年 8 月的病例增加了 170%。</p>
</div>

Bavarian Nordic 與 SII 簽署協議以生產基孔肯雅疫苗